Today: 14 November 2025
Subscribe
Browse Tag

analyst insights

Palantir (PLTR) Today: Stock Slips as Valuation Debate Heats Up—Fresh Analyst Notes, $455B Market-Cap Talk, and What’s Next (12.11.2025)

Palantir (PLTR) Today: Stock Slips as Valuation Debate Heats Up—Fresh Analyst Notes, $455B Market-Cap Talk, and What’s Next (12.11.2025)

Palantir Technologies Inc. (NASDAQ: PLTR) traded lower this morning after a blistering multi‑month rally. New opinion pieces and analyst chatter out today are zeroing in on the same tension investors have wrestled with all year: explosive AI-driven growth vs. a sky‑high valuation. What’s new today (and why the stock is down) Stock check: Shares were recently trading lower intraday (see live chart above). Market‑cap services place Palantir’s value roughly in the $440B–$455B range depending on price ticks and share‑count methodology. Yahoo Finance+2MarketWatch+2 The backdrop: jaw‑dropping Q3, equally intense scrutiny Palantir’s latest quarter (reported last week) was objectively strong: Management also
12 November 2025
 ·  ·  ·  ·  · 
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Stock Price & Recent Performance 📈 Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings report stockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32 investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now
5 November 2025
 ·  ·  ·  ·  · 
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases gurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S. gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis
3 November 2025
 ·  ·  ·  ·  · 
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases gurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last year investing.com. This record top-line was boosted by a one-time $275 M licensing deal with partner Sobi investing.com, which paid Apellis upfront for future ex-U.S. royalties on Aspaveli (Empaveli’s overseas brand). Thanks largely to this deal, Apellis swung to a net profit of $215.7 M (versus a $57.4 M loss a year ago) markets.businessinsider.com. However,
30 October 2025
 ·  ·  ·  · 
Costco Stock Surges Amid Retail Gloom – Will $900+ Shares Keep Climbing?

Costco (COST) Stock Slides to ~$924: Analyst Takeaways and Competitor Comparison (Oct 16, 2025)

Key Facts (Oct 16, 2025): – Costco shares traded around $924 today (Oct. 16), off roughly 3.4% from the prior close of $954.99 statmuse.com. – Fiscal Q4 2025 (ended Aug. 31) net sales were $84.4 billion (up 8.0% YoY) and net income $2.61 billion ($5.87 per share) investor.costco.com investor.costco.com, topping forecasts. – Same-store sales (excl. gas) rose 6.4%, slightly above analyst expectations reuters.com. – Membership fee revenue jumped 14% to $1.72 billion reuters.com. – Wall Street remains broadly bullish: consensus 12‑month price target ~$1,054 (≈18% above current) benzinga.com ts2.tech, with most analysts rating COST a “Buy.” – Peers on Oct. 16: Walmart ~105.7 USD (-2.6%) investing.com, Target ~89.1 USD (-1.4%) investing.com, BJ’s Wholesale ~94.2 USD (+0.1%) investing.com. – Economic backdrop: Deloitte projects sluggish holiday retail growth
16 October 2025
 ·  ·  ·  ·  · 
Charles Schwab Stock Surges on Blowout Q3 Results, Analysts Eye More Upside

Charles Schwab Stock Surges on Blowout Q3 Results, Analysts Eye More Upside

Schwab’s Q3 results illustrate a strong growth cycle: client assets are growing at a record pace and fee & trading revenues are robust. As Wurster put it, this reflects “strengthening organic growth trends” and “favorable macroeconomic tailwinds” powering another “quarter of record revenue and earnings per share” pressroom.aboutschwab.com. With analysts updating ratings upward (as detailed by Benzinga and Capital.com) and the stock trading near multi-year highs, the near-term outlook for SCHW is widely seen as upbeat benzinga.com capital.com. Investors will watch closely how this wealth-gathering momentum holds up if market conditions change. Sources: Company filings and press release (Oct. 16 2025) pressroom.aboutschwab.com
16 October 2025
 ·  ·  ·  ·  · 
Oklo (OKLO) Stock Goes Nuclear: DOE Contracts Trigger Explosive Rally – Analysts Weigh In

Oklo (OKLO) Stock Goes Nuclear: DOE Contracts Trigger Explosive Rally – Analysts Weigh In

Current Stock Performance Oklo’s stock has been extremely volatile in October 2025. On Oct 10 it traded in a $136.80–$161.35 range and closed at $147.16 stockinvest.us (a 6.5% gain for the day). Volume has surged (38.8M shares on Oct 10 vs ~16.6M on Oct 9) stockinvest.us. Year-to-date, the stock is up roughly 500% (even over 1,100% since late 2024) ts2.tech, reflecting explosive investor interest. For context, StockInvest.us notes the 52-week trading range is about $9–$161 stockinvest.us, illustrating how Oklo went from penny-stock levels post-SPAC to a ~$20B market cap in 2025 ts2.tech. Major Company Developments DOE Programs & Projects: In
13 October 2025
 ·  ·  ·  ·  ·  · 
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Skyrockets – Major News & Analyst Insights (Oct 2025)

Key Facts: Oscar Health’s stock recently jumped to roughly $21.5 on Oct 3, 2025 (up ≈11% that day) indmoney.com. Over the past week, the stock is up about 8% marketscreener.com. In Q2 2025, Oscar reported $2.9 billion revenue (+28–30% YoY) but a $228 million net loss ($0.89/share) due to a high medical loss ratio tradingview.com. Management has reaffirmed full-year 2025 guidance (revenues ~$11.2–11.3 B, operating income $225–275 M) at the Wells Fargo conference ainvest.com ainvest.com, and in July raised its revenue outlook to ~$12.0–12.2 B (but warned medical costs would be higher, with MLR ~86–87%) investing.com. Analysts are broadly bearish: MarketBeat shows a consensus “Strong
3 October 2025
 ·  ·  ·  ·  · 
Coal Comeback Sends Peabody Energy (BTU) Stock Soaring – Real-Time Update & Analyst Insights

Coal Comeback Sends Peabody Energy (BTU) Stock Soaring – Real-Time Update & Analyst Insights

Key Facts (as of Oct 3, 2025): U.S. markets are open (Fri Oct 3). Peabody Energy (NYSE: BTU) is trading around $31.0 per share (as of ~10:30 AM EDT), up roughly +5.9% on the day marketbeat.com. Trading volume is heavy (20-day avg ~5.4 M shares stockanalysis.com). Market Cap is ≈$3.9 billion stockanalysis.com. Key ratios: trailing P/E ≈28.8, forward P/E ~64 stockanalysis.com (reflecting squeezed near-term earnings); EPS (TTM) ≈$1.10 stockanalysis.com; Revenue ~$4.04 B (TTM) stockanalysis.com. Peabody pays a $0.30 annual dividend (~1.0% yield) stockanalysis.com (last declared $0.075 in Q3’25 investing.com). Financially, Peabody holds net cash (~$192M: $586M cash vs $394M debt stockanalysis.com) and book equity
3 October 2025
 ·  ·  ·  ·  · 
Go toTop